All In Biotech

Drug Trial Radar · NCT05216432

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Last checked: Nov 20, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

930

Planned (sponsor's estimate)

Start

Dec 8, 2021

Primary completion

Apr 30, 2027

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Relay Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will also evaluate RLY-2608 in combination RLY-2608 + fulvestrant and in triple combination RLY-2608 + fulvestrant + CDK4/6 inhibitor (palbociclib or ribociclib) or CDK4 inhibitor (PF-07220060) for patients with HR+ HER2- locally advanced or metastatic breast cancer. The RLY-2608 single agent arm, RLY-2608 + fulvestrant combination arm, and triple combination arms will have 2 parts: a dose escalation (Part 1) and a dose expansion (Part 2).

Conditions

  • PIK3CA Mutation
  • Solid Tumor, Adult
  • HER2-negative Breast Cancer
  • Breast Cancer
  • Metastatic Breast Cancer
  • Advanced Breast Cancer
  • Unresectable Solid Tumor

Interventions

  • RLY-2608Drug

    RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.

  • FulvestrantDrug

    500 mg fulvestrant is administered intramuscularly on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (where a cycle is 28 days).

  • Palbociclib 125mgDrug

    125mg palbociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.

  • Ribociclib 400mgDrug

    400mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.

  • Ribociclib 600mgDrug

    600mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.

  • PF-07220060 100mgDrug

    PF-07220060 100 mg is taken orally twice daily at the same time with RLY-2608 during each 28-day cycle.

  • PF-07220060 300 mgDrug

    PF-07220060 300 mg is taken orally twice daily at the same time with RLY-2608 during each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determination of maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of RLY-2608 as a single agentTime frame: Cycle 1 (4-week cycle) of treatment for MTD and at the end of every cycle (4-week cycles) for RP2D until study discontinuation, approximately 24 months
  2. Determination of maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of RLY-2608 in combination with fulvestrantTime frame: Cycle 1 (4-week cycle) of treatment for MTD and at the end of every cycle (4-week cycles) for RP2D until study discontinuation, approximately 24 months
  3. Determination of maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of RLY-2608 in combination with fulvestrant and a CDK 4/6 inhibitor (palbociclib, ribociclib), and in combination with CDK4 inhibitor (PF-07220060) and fulvestrantTime frame: Cycle 1 (4-week cycle) of treatment for MTD and at the end of every cycle (4-week cycles) for RP2D until study discontinuation, approximately 24 months
  4. Number of patients with adverse events and serious adverse events of RLY-2608 as a single agentTime frame: Every cycle (4-week cycles) until study discontinuation, approximately 24 months
  5. Number of patients with adverse events and serious adverse events of RLY-2608 in combination with fulvestrantTime frame: Every cycle (4-week cycles) until study discontinuation, approximately 24 months
  6. Number of patients with adverse events and serious adverse events of RLY-2608 in combination with fulvestrant and a CDK 4/6 inhibitor (palbociclib, ribociclib), and in combination with CDK4 inhibitor (PF-07220060) and fulvestrantTime frame: Every cycle (4-week cycles) until study discontinuation, approximately 24 months

Locations

37 sites in 5 countries. Site status is shown where the registry gives one.

  • The University of Arizona Cancer Center

    Tucson, Arizona · Recruiting

  • University of California-San Diego

    San Diego, California · Recruiting

  • HealthONE

    Denver, Colorado · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Florida Cancer Specialists

    Orlando, Florida · Recruiting

  • Boca Raton Clinical Research (BRCR) Global

    Plantation, Florida · Withdrawn

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • Community Health Network

    Indianapolis, Indiana · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Washington University School of Medicine St. Louis

    St Louis, Missouri · Recruiting

  • Renown Regional Medical Center

    Reno, Nevada · Recruiting

  • Rutgers University

    New Brunswick, New Jersey · Recruiting

  • NYU Langone

    New York, New York · Recruiting

  • Columbia University Herbert Irving Comprehensive Cancer Center

    New York, New York · Recruiting

  • Memorial Sloan Kettering

    New York, New York · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

  • The University of Texas M.D. Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Utah- Huntsman Cancer Center

    Salt Lake City, Utah · Recruiting

  • Inova Schar Cancer Center

    Fairfax, Virginia · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • UW Carbone Cancer Center

    Madison, Wisconsin · Recruiting

  • St Vincents Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Peter MacCallum Cancer Center

    Melbourne, Victoria, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Institute Bergonié

    Bordeaux, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • Centre Léon Bérard

    Lyon, Auvergne-Rhône-Alpes, France · Recruiting

  • Istituto Europeo di Oncologia IRCCS

    Milan, Italy · Recruiting

  • Institut Catala D'Oncologia - Badalona (ICO Badalona)

    Barcelona, Spain · Recruiting

  • START Madrid - Hospital Fundacion Jimenez Diaz

    Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Vall d'Hebron Instituto de Oncologia

    Barcelona, Barcelona, Spain · Recruiting

  • START Barcelona

    Barcelona, Catalonia, Spain · Recruiting

  • Instituto Valenciano de Oncologia

    Valencia, Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.